Methods of increasing lean tissue mass using OB protein...

Details Methods of increasing lean tissue mass using OB protein... Methods of increasing lean tissue mass using OB protein...

2007-04-24

2007-04-24

Chan, Christina (Department: 1644)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

C530S387100, C530S399000, C424S192100, C424S196110

Reexamination Certificate

active

11033600

ABSTRACT:
The present invention provides methods of creating and using OB protein compositions with an antibody constant region or portion thereof fused to an OB protein. The fusion protein is created by attaching the polyamino acids to the OB protein moiety. The fusion proteins can then be used for various therapeutic uses.

REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4925673 (1990-05-01), Steiner et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5073627 (1991-12-01), Curtis et al.
patent: 5098833 (1992-03-01), Lasky et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5169318 (1992-12-01), Levy
patent: 5225538 (1993-07-01), Capon et al.
patent: 5284656 (1994-02-01), Platz et al.
patent: 5349053 (1994-09-01), Landolfi et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5455165 (1995-10-01), Capon et al.
patent: 5480981 (1996-01-01), Goodwin et al.
patent: 5514582 (1996-05-01), Capon et al.
patent: 5594101 (1997-01-01), Becker et al.
patent: 5594104 (1997-01-01), Basinski et al.
patent: 5646040 (1997-07-01), Kleyn et al.
patent: 5670625 (1997-09-01), Baum et al.
patent: 5714147 (1998-02-01), Capon et al.
patent: 5739277 (1998-04-01), Presta et al.
patent: 5935810 (1999-08-01), Friedman et al.
patent: 6001968 (1999-12-01), Friedman et al.
patent: 6025325 (2000-02-01), Campfield et al.
patent: 6048837 (2000-04-01), Friedman et al.
patent: 6350730 (2002-02-01), Friedman et al.
patent: 2205572 (1995-12-01), None
patent: 2195955 (1996-02-01), None
patent: 2224646 (1997-01-01), None
patent: 2238307 (1997-07-01), None
patent: 306673 (1989-03-01), None
patent: 401384 (1989-12-01), None
patent: 362999 (1990-04-01), None
patent: 417563 (1991-03-01), None
patent: 464533 (1992-01-01), None
patent: 956862 (2002-12-01), None
patent: WO 89/10932 (1989-11-01), None
patent: WO 91/11111 (1991-08-01), None
patent: WO 92/13559 (1992-08-01), None
patent: WO 94/06476 (1994-03-01), None
patent: WO 96/03141 (1996-02-01), None
patent: WO 96/04388 (1996-02-01), None
patent: WO 96/05309 (1996-02-01), None
patent: WO 96/18412 (1996-06-01), None
patent: WO 96/22308 (1996-07-01), None
patent: WO 96/31526 (1996-10-01), None
patent: WO 97/00319 (1997-01-01), None
patent: WO 97/18833 (1997-05-01), None
patent: WO 97/24137 (1997-07-01), None
patent: WO 97/24440 (1997-07-01), None
patent: WO 98/28427 (1998-07-01), None
patent: WO 98/46257 (1998-10-01), None
patent: WO 99/02711 (1999-01-01), None
patent: WO 99/22764 (1999-05-01), None
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 491-495.
Skolnick et al., From genes to protein structure and function: novel applications of computational approaches in the genomic era, Jan. 2000, Trends in Biotech. 18(1): 34-39.
Mikayama et al, Molecular cloning and functional expression of a cDNA encoding gycosylation-inhibition factor, Nov. 1993, Proc. Natl. Acad. Sci, USA vol. 90: 10056-10060.
Attwood et al, The Babel of Bioinformatics, 2000, Science vol. 290 No. 5491: 471-473.
Abuchowski, A., et al., “Soluble Polymer-Enzyme Adducts,”Enzymes as Drugs(J.S. Holcerberg and J. Roberts, eds.) 367-383 (1981).
Adjei, et al.,Int'l. J. of Pharm.,61:135-144 (1990).
Adjei, et al.,Pharm. Res.,7(6):565-569 (1990).
Ashkenazi, A., et al.,A Companion to Methods in Enzymology,8:104-115 (1995).
Ashkenazi, A. et al., “Protection Against Edotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin,”PNAS USA,88:10535-39 (1991).
Attwood, T., et al., “The Babel of Bioinformatics,”Science290(5491):471-473 (Oct. 2000).
Bachmann, et al.,Bacteriol. Rev.,40:116-167 (1976).
Barinaga, M. “‘Obese’ Protein Slims Mice,”Science,269:475-476 (1995).
Bennett, B. et al., “Estracellular Domain-IGG Fusion Proteins for Three Human Natriuretic Peptide Receptors,”J. BioChem.266:(34) 23060-67 (1991).
Braquet, et al.,J. Cardiovascular Pharm.13(Supp. 5):S143-S146 (1989).
Campfield, L.A., et al., “Recombinant Mouse OB Protein: Evidence for a Peripheral Signal Liking Adiposity and Central Neural Networks,”Science,269:54-549 (1995).
Capon, D., et al., “Designing CD4 Immunoadhesins for AIDS Therapy,”Nature,337:525-531 (Feb. 9, 1989).
Debs, et al.,J. Immun.,140(10):3482-3488 (1988).
*Devos, R., et al., “OB Protein Binds Specifically to the Choroid Plexus of Mice and Rats,”Proc. Natl. Acad. Sci. USA,93:5668-5673 (May 1996).
Ellison, et al., “The Nucleotide Sequence of a Human Immunoglobulin Cγ1 Gene,”Nucleic Acids Research,10(13):4071-4079 (1982).
Fisher, C., et al., “Treatment of Septic Shock With the Tumor Necrosis Factor Receptor:Fc Fusion Protein,”N. Engl. J. Med.,334:1697-17022 (1996).
Francis,Focus on Growth Factors,3:4-10 (1992).
*Haak-Frendscho, M. et al., “Inhibition of Interferon-γ by an interferon-γ Receptor Immunoadhesin,”Immunology,79:594-599 (1993).
Halaas, et al., “Weight-Reducing Effects of the Plasma Protein Encoded by theObeseGene,”Science,269:543-546 (1995).
Harvey, et al.,Remington's Pharmaceutical Sciences,18thEd., (Mack Publishing Co., Easton, PA, ed. Gennaro 1990), p. 948-1001.
Harvill, E., et al., “An IgG3-IL2 Fusion Protein Activates Complement, Binds FcγRI, Generates LAK Activity and Shows Enhanced Binding to the High Affinity IL-2R,”Immunotechnology,1:95-105 (1995).
Ho, S.N., et al., “Site-Directed Mutagenesis by Overlap Extension Using the Polymerase Chain Reaction,”Gene,77:51-59 (1989).
Hollenbaugh, et al.,Current Protocols in Immunology,Supp. 4:10.19.1-10.19.11 (1992).
Hubbard, et al.,Annals of Internal Medicine,111(3):206-212 (1989).
Imagawa, K., et al., “Structure-Function Studies of Human Leptin,”J. Biological Chem.,273(52):35245-49 (1998).
*Kolaczynski, J., et al., “Acute and Chronic Effects of Insulin on Leptin Production in Humans: Studies in vivo and in vitro.”Diabetes,45(5):699-701 (1996).
Leshner, et al.,Physiology and Behavior,9:281-282 (1972).
*Luoh, S-M., et al.,J. Mol. Endo.,18:77-85 (1997).
MacDonald, et al.,Methods in Enzymology,152:219-227 (1987).
Malik, F., et al., “Polyethylen Glycol (PEG)-modifided Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF) with Conserved Biological Activity,”Exp. Hematol.,20:1028-1035 (1992).
Mark, M., et al., “Expression and Characterization of Hepatocyte Growth Factor Receptor-IgG Fusion Proteins,”J. Bio Chem.,267:(36) 26166-71 (1992).
Marshall,Modern Pharmaceutics(Marcel Dekker, Inc., NY, eds. Banker and Rhodes 1979) p. 359-427.
Mikayama, T., et al. Molecular Cloning and Functional Expression of a cDNA Encoding Glycosylation-Inhibiting Factor, Nov. 1993,Proc. Natl. Acad. Sci., USA,90:10056-10060.
Murakami, T., et al., “Cloning of RatObesecDNA and Its Expression in Obese Rats,”Biochem. Biophys. Res. Comm.,209(3):944-952 (1995).
Newmark, et al.,J. Appl. Biochem.4:185-189 (1982).
Ngo, et al., The Protein Folding Problem and Tertiary Structure Prediction, pp. 491-495.
Oeswein, et al., “Aerosolization of Proteins,”Proceedings of Symposium on Respiratory Drug Delivery II,Keystone, CO, Mar. 1990.
Pelleymounter, M.A., et al., “Effects of theObeseGene Product on Body Weight Regulation inob/obMice,”Science,269:540-543 (1995).
Prescott, et al.,Microbiology(1990, Wm. C. Brown Publ., Dubuque, IA 52001) p. 599-602.
Remington's Pharmaceutical Sciences,18thEd. (1990, Mack Publishing Co., Easton, PA 18042) p. 1435-1712 (Table of Contents Provided).
Remington's Pharmaceutical Sciences,18thEd. (1990, Mack Publishing Co., Easton, PA 18042) Chapter 89 (Table of Contents Provided).
Sambrook, et al.,Molecular Cloning: A Laboratory Manual,2d Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (Table of Contents Provided).
Skolnick, et al., “From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era,”Trends in Biotech.,18(1):34-39 (Jan. 2000).
Shin

Affiliated with

Also associated with

Rating

Methods of increasing lean tissue mass using OB protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of increasing lean tissue mass using OB protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of increasing lean tissue mass using OB protein... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3780073